DIETHYLSTILBESTROL - RECOMMENDED DOSAGES FOR DIFFERENT CATEGORIES OF BREAST-CANCER PATIENTS - REPORT OF COOPERATIVE BREAST-CANCER GROUP
DIETHYLSTILBESTROL - RECOMMENDED DOSAGES FOR DIFFERENT CATEGORIES OF BREAST-CANCER PATIENTS - REPORT OF COOPERATIVE BREAST-CANCER GROUP
复制标题
DOI：
10.1001/jama.237.19.2079
复制
发表时间：
1977-01-01
影响因子：
120.7
通讯作者：
POTTER, NR
中科院分区：
文献类型：
--
作者：
CARTER, AC;SEDRANSK, N;POTTER, NR
共有523名绝经后进展性乳腺癌患者进入了一项随机双盲研究，研究人员使用四种剂量的己烯雌酚（DES）： 1.5、15、150或1500mg /天。剂量越大，回归率越高（P < 0.05）： 1500mg剂量为21%，150mg剂量为17%，15mg剂量为15%，1.5 mg剂量为10%。无论使用何种剂量诱导，回归的持续时间都是相似的。虽然最高剂量总体上产生最高的消退率，但根据绝经年龄和主要转移部位为每种类型的患者选择最佳剂量或治疗选择将导致更多的消退。
A total of 523 postmenopausal breast cancer patients with progressive disease were entered in a randomized, double blind study of 4 dosages of diethylstilbestrol (DES): 1.5, 15, 150 or 1500 mg/day. Higher dosages produced significantly (P < .05) higher regression rates: 21% for the 1500 mg dosage, 17% for the 150 mg dosage, 15% for the 15 mg dosage and 10% for 1.5 mg dosage. Durations of regressions were similar regardless of the dosages used to induce them. Although the highest dosage produced the highest regression rate overall, selecting the best dosage or treatment of choice for each type of patient based on menopausal age and dominant metastatic site would result in more regressions.